Ligand Pharmaceuticals LGND Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $153.56M+23.4% | $124.45M+156% | $48.58M+164% | -$75.86M+42.8% | -$132.62M-3,189% | ||
| $33.22M-1.6% | $33.78M-1.2% | $34.19M-2.1% | $34.91M-0.9% | $35.24M0.0% | ||
| $49.61M+5.9% | $46.85M+16.8% | $40.1M-1.0% | $40.53M-2.6% | $41.59M+1.2% | ||
| $123.5M+150% | $49.36M+54.7% | $31.92M-42.3% | $55.36M+4.7% | $52.87M-45.5% | ||
| $466K+3.1% | $452K-60.9% | $1.16M-33.5% | $1.74M-10.1% | $1.93M+6.0% | ||
| -$476.56M-26.3% | -$377.32M+5.2% | -$397.84M-338% | -$90.9M+32.7% | -$135M+6.0% | ||
| $418.84M-2.2% | $428.22M-2.7% | $440.28M+414% | $85.72M+6.9% | $80.21M-17.4% | ||
| $67.11M-34.6% | $102.62M+35.5% | $75.76M+53.0% | $49.53M+2,454% | -$2.1M-104% | ||
| $123.03M+152% | $48.91M+59.0% | $30.76M-42.6% | $53.62M+5.3% | $50.94M-46.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Ligand Pharmaceuticals's cash flow data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.